Advancements in technology has allowed breast cancer to be further classified into different subtypes based upon molecular markers defined by immunohistochemistry (IHC): Estrogen (ER)/progesterone (PR), human epidermal growth factor receptor 2 (HER2), or triple negative breast cancer [2]. This evidence concerns the gene ERBB2 and breast cancer.